National Comprehensive Cancer Network’s patient information team provides a patient and caregiver version of recently-updated, evidence-based expert consensus recommendations for vaccinating people with cancer against COVID-19.
Free resource from the National Comprehensive Cancer Network helps employers select health plans and provide services to improve employee outcomes and minimize disruptions from cancer diagnoses—now available at NCCN.org/employertoolkit
National Comprehensive Cancer Network announces recipients of 2021 NCCN Foundation Young Investigator Awards; projects from early-career investigators to advance research in cancer prevention, racial disparities in screening, immunotherapy, new insights in radiotherapy, and CAR T-cell therapy.
NCCN announced that it has elected University of California (UC) Davis Comprehensive Cancer Center as its newest Member Institution joining 30 other leading academic cancer centers to improve and facilitate quality, effective, efficient, and accessible cancer care so patients can live better lives.
National Comprehensive Cancer Network Oncology Research Program selects ten projects to receive funding to study the safe, effective, and efficient adoption of biosimilars in oncology.
Results of new study in JNCCN from Mass General Hospital Cancer Center, Harvard Medical School, and Dana-Farber Cancer Institute underscore the need for the development and testing of nutrition and fitness interventions, as muscle quality significantly correlates with symptom burden, healthcare utilization, and survival.
The National Comprehensive Cancer Network (NCCN), American Cancer Society Cancer Action Network (ACS CAN) and the National Minority Quality Forum (NMQF) presented new ideas for overcoming inequality in oncology. The recommendations address how medical systems often disproportionately fail minority patients.
National Comprehensive Cancer Network publishes first-ever complete medical guidelines for a pediatric solid tumor, so children everywhere receive the best care based on the latest research. NCCN Guidelines for Wilms Tumor shares information for earlier, safer diagnosis and treatment in effort to reduce disparities; doctors warn of late diagnosis as a possible impact from the COVID-19 pandemic.
New research in the February 2021 issue of JNCCN examined body mass index (BMI) data for people with HER2-positive early breast cancer, and found a 5% weight loss in patients over two years in was associated with worse outcomes. Weight gain over the same time period did not affect survival rates.
The National Comprehensive Cancer Network® (NCCN®) today announced the appointment of Patrick Delaney as incoming Executive Director for the NCCN Foundation®. Delaney has previously held leadership roles with the Juvenile Diabetes Research Foundation, American Red Cross, and American Cancer Society.
For World Cancer Day 2021, National Comprehensive Cancer Network (NCCN) employees took part in a 21-day challenge to get personal about cancer care, by sharing a look at how different staff members’ lives have been directly impacted by cancer.
The National Comprehensive Cancer Network (NCCN) and the American Cancer Society (ACS) are teaming up with leading cancer organizations across the country to endorse prioritizing the safe resumption of cancer screening and treatment during the ongoing COVID-19 pandemic. The coalition of 76 organizations is releasing an open letter about the threat cancer still poses to people’s health and a reminder that acting as soon as is safely possible can lead to much better outcomes in the future.
The National Comprehensive Cancer Network put out new guidance for COVID-19 vaccinations in people with cancer, based on available evidence plus consensus from top hematology and oncology experts with particular expertise in infectious diseases, vaccine development and delivery, and medical ethics.
The National Comprehensive Cancer Network (NCCN) announces Crystal S. Denlinger, MD, FACP, as incoming Senior Vice President, Chief Scientific Officer. Dr. Denlinger will help to steer strategic direction for the nonprofit as well as oversee the NCCN Oncology Research Program (ORP).
NCCN announces the publication of new, free informational resources on health and wellness for cancer survivors. Two new NCCN Guidelines for Patients® focus on healthy living and managing late and long-term side effects, and include appropriate ongoing screening for recurrence.
National Comprehensive Cancer Network Oncology Research Program announces selected studies on adding axitinib, an oral VEGF inhibitor, to treatment for melanoma, colorectal cancer, and hepatocellular carcinoma (HCC), in collaboration with Pfizer.
Virtual NCCN Policy Summit from the National Comprehensive Cancer Network explores how health policymakers can respond to the needs and wishes of people with cancer across all ages.
The NCCN Oncology Research Program (ORP) today announced five projects selected to receive funding for clinical and preclinical evaluation of abemaciclib, a cyclin dependent kinase (CDK) 4 & 6 inhibitor used in the treatment of HR+ and HER2- breast cancer.
New research in the November 2020 issue of JNCCN identifies metastatic pancreatic cancer patient subgroups with the highest relative cost-effectiveness from maintenance olaparib, a PARP inhibitor.
The National Comprehensive Cancer Network® (NCCN®) today announced the addition of Beth Gaffney, MBA, as the new Vice President of U.S. and Global Business Development, overseeing licensing and other collaborations.
Ongoing updates are underway for NCCN Guidelines for Breast Cancer in Chinese, English, French, Japanese, Korean, Spanish, Polish, and Portuguese, free online at NCCN.org/global. Follow #NCCNGlobal for more. The NCCN Foundation is hosting free metastatic breast cancer webinars for patients and caregivers on October 8 and 12 at NCCN.org/patients.
The National Comprehensive Cancer Network announces publication of new NCCN Guidelines for Pediatric Hodgkin Lymphoma, one of the most curable forms of pediatric cancer. They synthesize the latest evidence and expert-consensus to make sure every child receives appropriate, but not excessive, treatment.
NCCN publishes a new patient and caregiver resource focused on a childhood cancer type. Free NCCN Guidelines for Patients: Pediatric Acute Lymphoblastic Leukemia (ALL) shares the latest expert advice for treating infants, children, and adolescents with the most common pediatric malignancy.
NCCN Virtual Policy Summit features congressional staffers and representatives from CMS, COA, BIO, and others, discussing legislative and regulatory approaches for reducing health care costs.
New international research in the September 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds immunotherapy-related adverse events (irAEs) can impact more than one organ in a single patient. Multi-organ irAEs are more likely to happen sequentially rather than simultaneously.
NCCN announces new and updated Chinese language versions of NCCN Guidelines for AML, Breast Cancer, CLL/SLL, Colon Cancer, Gastric Cancer, Hairy Cell Leukemia, Head and Neck Cancers, Hodgkin Lymphoma, Melanoma (Cutaneous), Multiple Myeloma, Non-small Cell Lung Cancer, Primary Cutaneous Lymphomas, and T-Cell Lymphomas.
The NCCN Virtual Nursing Forum and Annual Congress: Hematologic Malignancies (#NCCNhem2020) will provide the latest evidence and expert consensus on emerging practices and debates in blood cancer treatment, online October 8-10.
The NCCN Oncology Research Program (ORP) today announced four projects selected to receive funding for clinical and pre-clinical evaluation of futibatinib (TAS-120) in collaboration with Taiho Oncology.
National Comprehensive Cancer Network issues Request for Proposals (RFP) for projects that develop and validate enduring approaches to improve the safe, effective, and efficient adoption of biosimilars in oncology.
The NCCN Distress Thermometer enables discussion and treatment of distress as part of routine care for people with cancer. This free resource is now translated into 46 languages for global accessibility.
New research from the University of California, San Francisco (USCF) and City of Hope in the July 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network examines coverage trends for circulating tumor DNA testing, also known as gene sequencing of ctDNA or “liquid biopsies.” The researchers found coverage rate rose from 0% to 38% in three years. The policies also increased in scope from 2017-2019, going from one cancer type to 12.
The National Comprehensive Cancer Network (NCCN) has published a new NCCN Guidelines for Patients: Immunotherapy Side Effects focused on chimeric antigen receptor (CAR) T-cell therapy. This is book two in a series that includes another book on irAEs focused on immune checkpoint inhibitors.
New NCCN Guidelines for Patients: Immunotherapy Side Effects – Immune Checkpoint Inhibitors from National Comprehensive Cancer Network and NCCN Foundation shares information for patients and caregivers on how to recognize and manage adverse events from immune checkpoint inhibitors.
NCCN Guidelines for Pediatric Acute Lymphoblastic Leukemia (ALL) in Chinese, Japanese, French, Spanish, and Portuguese are now available for free at NCCN.org
Online summit from NCCN on 21st Century Cures Act includes bipartisan sponsors, regulatory authorities; examines the impact on and from COVID-19 on cancer care and technology; presents policy recommendations for using data to advance patient access to high-quality cancer care
New research from Mass General Cancer Center, published in the June 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network, found 40.2% of hospitalized patients with advanced, incurable cancer were functionally impaired at the time of admission.
Newly-completed series of patient guidelines from National Comprehensive Cancer Network (NCCN) shares expert advice with patients and caregivers on treatment and prevention for most common head and neck cancers, including some that are HPV-related.
NCCN and the NCCN Foundation announce five new recipients for the 10th annual NCCN Foundation Young Investigator Awards (YIA) Program, overseen by the NCCN Oncology Research Program (ORP)
The NCCN 2020 Annual Conference (#NCCN2020) providing the latest updates on cancer treatment recommendations was initially postponed due to COVID-19. The CE-accredited sessions are now available as online webinars.
A recently-published, independent, peer-reviewed, international study in Current Urology measured reliability and transparency of online medical information for people with prostate cancer and their caregivers, and found the NCCN Guidelines for Patients® to be one of the most trustworthy resources.
NCCN Best Practices Committee publishes peer-reviewed feature in JNCCN presenting latest insights on how to keep oncology patients and healthcare workers safe during COVID-19 pandemic. Visit NCCN.org/covid-19 for continually-updated resources for patients, providers, and care systems.
National Comprehensive Cancer Network (NCCN) announces addition of UCLA Jonsson Comprehensive Cancer Center and
UT Southwestern Simmons Comprehensive Cancer Center to not-for-profit alliance of leading cancer centers responsible for creating and updating NCCN Guidelines among other oncology activity.
Experts from Seattle Cancer Care Alliance share lessons learned from early experiences treating people with cancer during COVID-19 outbreak via free online article in JNCCN—Journal of the National Comprehensive Cancer Network
New research from the American Cancer Society in the March 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that younger cancer survivors are more likely to experience significant financial strain for food, housing, and monthly bills after diagnosis.
The National Comprehensive Cancer Network (NCCN) has published a curated list of high-impact measures for assessing quality improvements in cancer care. The recommendations reflect a landscape analysis from leading oncology experts in order to move the needle on cancer care standards in America.
National Comprehensive Cancer Network Postpones 2020 Annual Conference, Citing Precautions against Potential Patient Exposure to COVID-19
Largest population-based analysis on factors that affect survival outcomes for HPV-positive oropharyngeal squamous cell carcinoma of the head and neck (SCCHN) find significant racial and socioeconomic disparities, according to new study in JNCCN-Journal of the National Comprehensive Cancer Network.
The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) announces plans to evaluate futibatinib (TAS-120), an inhibitor of the fibroblast growth factor receptor (FGFR).
NCCN hosted an annual NCCN Patient Advocacy Summit: Delivering Value for Patients across the Oncology Ecosystem in Washington, DC, bringing together patients, advocates, clinicians, policy-makers, and others to share diverse perspectives on the meaning of value in cancer care.
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announces proposals selected for funding, in collaboration with Pfizer Global Medical Grants, to improve the quality of care and outcomes for people with metastatic breast cancer (MBC).